- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/18 - Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Patent holdings for IPC class A61P 25/18
Total number of patents in this class: 3357
10-year publication summary
|
108
|
111
|
148
|
199
|
240
|
213
|
253
|
271
|
225
|
62
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2961 |
95 |
| Janssen Pharmaceutica N.V. | 3839 |
75 |
| F. Hoffmann-La Roche AG | 7958 |
68 |
| H. Lundbeck A/S | 1252 |
59 |
| AstraZeneca AB | 3042 |
49 |
| Glaxo Group Limited | 4496 |
47 |
| Taisho Pharmaceutical Co., Ltd. | 844 |
43 |
| Intra-Cellular Therapies, Inc. | 378 |
34 |
| Boehringer Ingelheim International GmbH | 4629 |
33 |
| Pfizer Inc. | 3322 |
33 |
| Sumitomo Dainippon Pharma Co., Ltd. | 226 |
32 |
| Hoffmann-La Roche Inc. | 3060 |
31 |
| Sunovion Pharmaceuticals Inc. | 326 |
29 |
| Astellas Pharma Inc. | 1145 |
26 |
| Dainippon Sumitomo Pharma Co., Ltd. | 234 |
24 |
| Wyeth | 632 |
23 |
| Neurocrine Biosciences, Inc. | 381 |
21 |
| Sage Therapeutics, Inc. | 312 |
21 |
| Merck Sharp & Dohme LLC | 3689 |
20 |
| Novartis AG | 11238 |
19 |
| Other owners | 2575 |